BioStrategies LC
BioStrategies LC specializes in the development of novel therapeutics for the treatment of Rare Diseases. To this purpose, BSLC has received multiple grant awards from NIH and other federal and state agencies to support its innovative research program. BioStrategies continues to bring novel technologies to therapeutics for rare disease with the development of new lectin-based protein delivery syst
This week our Senior Scientist Tianhong Yang is attending the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles CA. We are very excited to share our research and learn the advances in the gene therapy field.
10/07/2014
Congratulations to Dr. Carole Cramer: ABI 2014 Established Investigator of the Year Award
08/12/2014
MPS 2014 at Brazil
06/27/2012
This Tibbetts Award SBIR nomination highlights twenty years of successful SBIR research led by the team of Drs. David Radin and Carole Cramer, who have pioneered R&D leading to the introduction of bioengineered plants for manufacturing human therapeutic proteins. Their core innovation was achieved during their first SBIR award from NIH in 1993 which demonstrated that the normal gene for a human enzyme responsible for a rare genetic disease called Gauchers disease could be transformed into into plants and expressed to produce a bioactive human enzyme. This technology is expected to bethe first human therapeutic protein to achieve FDA approval for marketing in the US this spring.
Click here to claim your Sponsored Listing.
Category
Website
Address
504 University Loop E
Jonesboro, AR
72401
Opening Hours
| Monday | 8am - 5pm |
| Tuesday | 8am - 5pm |
| Wednesday | 8am - 5pm |
| Thursday | 8am - 5pm |
| Friday | 8am - 5pm |